Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M11,103Revenue $M1,134Net Margin (%)-36.6Altman Z-Score1.3
Enterprise Value $M13,424EPS $-6.5Operating Margin %-43.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-58.5Higher ROA y-yN
Price/Book46.210-y EBITDA Growth Rate %--Quick Ratio0.6Cash flow > EarningsY
Price/Sales10.25-y EBITDA Growth Rate %--Current Ratio0.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-195.1ROA % (ttm)-9.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-71.0Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M63.7ROIC % (ttm)-11.5Gross Margin Increase y-yN

Gurus Latest Trades with SLXP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SLXPMario Gabelli 2015-03-31 Buy 0.4%$112.84 - $172.81
($146.8)
$ 172.8118%New holding442,350
SLXPGeorge Soros 2015-03-31 Reduce-0.37%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce 58.92%201,903
SLXPFirst Eagle Investment 2015-03-31 Buy 0.2%$112.84 - $172.81
($146.8)
$ 172.8118%New holding479,891
SLXPJohn Paulson 2015-03-31 Reduce-0.18%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce 5.27%5,500,000
SLXPRuane Cunniff 2015-03-31 Buy 0.02%$112.84 - $172.81
($146.8)
$ 172.8118%New holding20,000
SLXPJohn Paulson 2014-12-31 Buy 3.4%$91.47 - $152.87
($120.33)
$ 172.8144%New holding5,806,000
SLXPGeorge Soros 2014-12-31 Buy 0.62%$91.47 - $152.87
($120.33)
$ 172.8144%New holding491,531
SLXPVanguard Health Care Fund 2014-12-31 Sold Out -0.61%$91.47 - $152.87
($120.73)
$ 172.8143%Sold Out0
SLXPVanguard Health Care Fund 2014-09-30 Reduce-0.09%$127.75 - $169.17
($144.97)
$ 172.8119%Reduce 15.70%1,538,045
SLXPJoel Greenblatt 2014-06-30 Sold Out -0.48%$97.7 - $125.07
($110.33)
$ 172.8157%Sold Out0
SLXPVanguard Health Care Fund 2014-06-30 Reduce-0.06%$97.7 - $125.07
($110.42)
$ 172.8157%Reduce 10.25%1,824,545
SLXPJoel Greenblatt 2014-03-31 Buy 0.48%$88.8 - $114.64
($101.95)
$ 172.8170%New holding307,445
SLXPVanguard Health Care Fund 2014-03-31 Reduce-0.03%$89.09 - $114.64
($102.39)
$ 172.8169%Reduce 5.36%2,032,845
SLXPJoel Greenblatt 2013-09-30 Sold Out -0.36%$65.73 - $75.54
($68.97)
$ 172.81151%Sold Out0
SLXPJoel Greenblatt 2013-06-30 Buy 0.36%$47.72 - $66.83
($57.19)
$ 172.81202%New holding127,495
SLXPJoel Greenblatt 2013-03-31 Sold Out -0.15%$40.472 - $51.37
($47.96)
$ 172.81260%Sold Out0
SLXPVanguard Health Care Fund 2013-03-31 Add0.08%$40.472 - $51.37
($47.96)
$ 172.81260%Add 22.44%2,147,945
SLXPNWQ Managers 2012-12-31 Sold Out -0.17%$37.97 - $42.9
($40.82)
$ 172.81323%Sold Out0
SLXPJoel Greenblatt 2012-12-31 Add0.06%$37.97 - $42.9
($40.82)
$ 172.81323%Add 75.81%63,399
SLXPVanguard Health Care Fund 2012-12-31 Add0.02%$37.97 - $42.9
($40.81)
$ 172.81323%Add 12.87%1,754,300
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SLXP is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SLXP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Forbes William PPresident, Medical R&D and CDO 2015-03-09Sell42,880$157.849.48view
CREECH TIMOTHY JSee Remarks 2015-03-06Sell4,600$157.679.6view
Scruggs Rick DExecutive Vice President 2015-03-06Sell4,000$157.559.69view
Forbes William PEVP Research&Devel & CDO 2015-03-06Sell20,000$157.969.4view
Forbes William PEVP Research&Devel & CDO 2014-11-12Sell11,079$95.0581.81view
CREECH TIMOTHY JSee Remarks 2014-11-05Sell0$081.81view
LOGAN CAROLYN JPresident & CEO 2014-06-26Sell53,057$123.3840.06view
Scruggs Rick DExecutive Vice President 2014-05-16Sell900$105.6763.54view
D ALONZO THOMASDirector 2014-04-22Sell11,530$110.8955.84view
CHAPPELL JOHN FDirector 2014-03-04Sell10,000$112.254.02view

Press Releases about SLXP :

    Quarterly/Annual Reports about SLXP:

    News about SLXP:

    Articles On GuruFocus.com
    Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015 
    Locust Wood Capital Bet on Top Performer Valeant Pharmaceuticals May 14 2015 
    Jean-Marie Eveillard Buys Flowserve, W W Grainger May 11 2015 
    Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 
    Looking Ahead of Wall Street: Salix Pharmaceuticals, Receptos, Tetraphase Mar 02 2015 
    Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
    John Paulson's Top Buys Feb 21 2015 

    More From Other Websites
    FDA Clears Two Irritable Bowel Syndrome Treatments May 27 2015
    After Salix acquisition, Valeant receives FDA approval for IBS-D drug May 27 2015
    Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015
    Drug maker Endo strikes again with $8bn bid for US rival May 18 2015
    More Waves In Pharma: Endo Buys TPG Capital's Par Pharma for $8 Billion May 18 2015
    John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba May 16 2015
    Big name investors take sides on Ackman bet on Valeant: filings May 15 2015
    JetBlue Airways Corporation (JBLU), Twenty-First Century Fox Inc (FOX): CQS Cayman’s Top Picks for... May 14 2015
    Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers May 01 2015
    Valeant Pharmaceuticals Reports In-Line Earnings, Ups View - Analyst Blog May 01 2015
    Valeant Pharmaceuticals (VRX) Earnings Report: Q1 2015 Conference Call Transcript Apr 30 2015
    Valeant Beats Q1 Views, Lifts Guidance, Loses CFO Apr 29 2015
    Valeant raises outlook after completing purchase of Salix Apr 29 2015
    Valeant raises outlook after completing purchase of Salix Apr 29 2015
    Valeant Boosts 2015 Outlook as Results Top Views Apr 29 2015
    Valeant Profit Tops Analysts’ Estimates as Drug Sales Surge Apr 29 2015
    5 deals that will change the corporate landscape in the southern U.S. Apr 28 2015
    Shire Gets Dropped from AQR Capital’s Portfolio Apr 23 2015
    Will the Salix-Valeant story play out over and over again? Apr 23 2015
    Lone Pine Reduces Its Stake in Valeant Pharmaceuticals Apr 22 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK